Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line encorafenib + cetuximab with or without chemotherapy versus standard of care in BRAF V600E-mutant metastatic colorectal cancer
2023-509405-77-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial of encorafenib and cetuximab in colorectal cancer (CRC) and colorectal adenocarcinoma (7 arms), sponsored by Pfizer. Primary endpoints: Incidence of dose-limiting toxicities, Progression-free survival by blinded independent central review and 1 more. Planned start Feb 2021; status: authorised.
02
Drugs
encorafenibcetuximab
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2023-509405-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509405-77-00.